Literature DB >> 2314484

Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment.

J Harro1, M Põld, E Vasar.   

Abstract

Effects of caerulein, a cholecystokinin octapeptide (CCK-8) receptor agonist, on exploratory activity of mice were investigated. Exploratory and locomotor activity of animals were measured using elevated plus-maze and open field tests. The systemic administration of caerulein at non-sedative doses (100 ng/kg-1 micrograms/kg i.p.) resulted in a significant decrease in the exploratory activity of mice. This effect was completely blocked by proglumide, a CCK-8 receptor. Acute treatment with low doses (0.1-0.75 mg/kg i.p.) of diazepam did not attenuate the anxiogenic-like effect of caerulein, but at more high doses of diazepam the coadministration depressed locomotor activity in mice. After subchronic diazepam treatment (2.5 mg/kg once a day, 10 days, i.p.) tolerance was developed toward the sedative effect of diazepam, and 72 h after withdrawal of the drug the animals showed increased anxiety in the plus-maze test. 30 min after the last injection procedure the anxiogenic-like effect of caerulein (500 ng/kg i.p.) on exploration was absent in both diazepam or vehicle groups. However, 72 h after the last pretreatment injection caerulein (500 ng/kg i.p.) reduced significantly the exploratory activity in control group, whereas it was inactive after diazepam withdrawal. The results obtained in this study support the hypothesis that endogenous CCK-8 an CCK-8 receptors are involved in the neurochemistry of anxiety and the anxiolytic action of benzodiazepine tranquillizers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2314484     DOI: 10.1007/bf00195059

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  24 in total

1.  Responsiveness of mesolimbic, mesocortical, septal and hippocampal cholecystokinin and substance P neuronal systems to stress, in the male rat.

Authors:  R A Siegel; E M Düker; E Fuchs; U Pahnke; W Wuttke
Journal:  Neurochem Int       Date:  1984       Impact factor: 3.921

2.  Competition for sucrose-pellets in triads of male Wistar rats: the individuals' performances are differing but stable.

Authors:  C Gentsch; M Lichtsteiner; H Feer
Journal:  Behav Brain Res       Date:  1988-01       Impact factor: 3.332

3.  The use of a plus-maze to measure anxiety in the mouse.

Authors:  R G Lister
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

4.  Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat.

Authors:  S Pellow; P Chopin; S E File; M Briley
Journal:  J Neurosci Methods       Date:  1985-08       Impact factor: 2.390

5.  Caerulein antagonism by benzodiazepines in the food intake in mice.

Authors:  K Kubota; K Sugaya; I Matsuda; Y Matsuoka; M Itonaga
Journal:  Jpn J Pharmacol       Date:  1985-09

Review 6.  Cholecystokinin in the central nervous system: a minireview.

Authors:  M C Beinfeld
Journal:  Neuropeptides       Date:  1983-10       Impact factor: 3.286

7.  Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones.

Authors:  J Bradwejn; C de Montigny
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

8.  Behavioral differences in an elevated plus-maze: correlation between anxiety and decreased number of GABA and benzodiazepine receptors in mouse cerebral cortex.

Authors:  L Rägo; R A Kiivet; J Harro; M Pŏld
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

9.  Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: a microiontophoretic study in the rat.

Authors:  J Bradwejn; C De Montigny
Journal:  Eur J Pharmacol       Date:  1985-06-19       Impact factor: 4.432

10.  Aversive and appetitive properties of anxiogenic and anxiolytic agents.

Authors:  S E File
Journal:  Behav Brain Res       Date:  1986-09       Impact factor: 3.332

View more
  10 in total

1.  Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, an agonist of CCK receptors, in the elevated plus-maze.

Authors:  E Vasar; E Peuranen; T Oöpik; J Harro; P T Männistö
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

2.  Effects of the CCKB antagonist L-365, 260 on benzodiazepine withdrawal-induced hypophagia in rats.

Authors:  A J Goudie; M J Leathley
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

3.  Social isolation of rats increases the density of cholecystokinin receptors in the frontal cortex and abolishes the anti-exploratory effect of caerulein.

Authors:  E Vasar; E Peuranen; J Harro; A Lang; L Oreland; P T Männistö
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

4.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

5.  Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.

Authors:  H J van Megen; H G Westenberg; J A den Boer; J R Haigh; M Traub
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

6.  Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.

Authors:  J Bradwejn; D Koszycki; A Couëtoux du Tertre; M Paradis; M Bourin
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

Review 7.  Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models.

Authors:  Susan Rotzinger; Franco J Vaccarino
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

8.  Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.

Authors:  N J Johnson; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

9.  Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.

Authors:  L Singh; A S Lewis; M J Field; J Hughes; G N Woodruff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

Review 10.  Neurobiological investigations into the role of cholecystokinin in panic disorder.

Authors:  J Bradwejn
Journal:  J Psychiatry Neurosci       Date:  1993-07       Impact factor: 6.186

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.